Palisade Bio Development Partner Newsoara Report the First Patient Enrolment of LB1148 in P-III Trial to protect Gastrointestinal Integrity in Surgery Patients
Shots:
- The first patient has been enrolled in an ongoing P-III trial evaluating LB1148. Enrolled patients will have a scheduled bowel resection procedure that will either use a laparotomy or a laparoscopic surgical approach & trial is being conducted & funded by Newsoara
- LB1148, a broad-spectrum serine protease inhibitor showed a positive result in reducing the incidence & severity of post-surgical abdominal adhesions and accelerating the time to return of postoperative bowel function in the clinical studies
- Newsoara is responsible for fully performing & funding the development in China, incl. the P-III study. Palisade will receive milestones upon achievement along with royalty on future annual net sales of LB1148 in Greater China
Ref: Globe Newswire | Image: Palisade Bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
